Fuxiang Shares: Announcement on the penalties or regulatory measures taken by securities regulatory authorities and exchanges in the past five years and their rectifications
Securities code: 300497 Securities abbreviation: Fuxiang Shares Announcement number: 2026-070
Jiangxi Fuxiang Pharmaceutical Co., Ltd.
Regarding penalties imposed by securities regulatory authorities and exchanges in the past five years or
Announcement on the adoption of regulatory measures and rectification situations
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Since its listing in December 2015, Jiangxi Fuxiang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has strictly complied with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Shenzhen Stock Exchange GEM Stock Listing Rules, the Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies, and the company's Articles of Association and other relevant regulations, constantly improving the company's standardized operation level, and promoting the company's sustainable, stable and healthy development.
In view of the company's plan to issue A shares to specific targets in 2026, in accordance with relevant laws and regulations, the company conducted a self-examination to see if there have been any penalties or regulatory measures taken by securities regulatory authorities and exchanges in the past five years. The self-examination status is now announced as follows:
1. The company has been punished by securities regulatory authorities and exchanges in the past five years
The company has not been punished by securities regulatory authorities or exchanges in the past five years.
- The company’s regulatory measures, disciplinary actions and rectifications taken by securities regulatory authorities and exchanges in the past five years
(1) Shenzhen Stock Exchange’s “Supervisory Letter on Bao Jianhua, the Actual Controller and Chairman of Jiangxi Fuxiang Pharmaceutical Co., Ltd., and Persons Acting in Concert” (GEM Supervisory Letter [2021] No. 55), China Securities Regulatory Commission Jiangxi Supervision Bureau’s “Decision on Taking Measures to Issue Warning Letters against Bao Jianhua, Jingdezhen Fuxiang Investment Co., Ltd., Bao Danhong, and Ke Xili” ([2021] No. 5).
On April 21, 2021, the company received the "Supervision Letter Regarding the Actual Controller and Chairman of Jiangxi Fuxiang Pharmaceutical Co., Ltd. Bao Jianhua and its Concerted Acting Persons" (GEM Supervision Letter [2021] No. 55) from the GEM Company Management Department, and in 2021 On August 4, 2020, the Jiangxi Supervision Bureau received the "Decision on Issuing Warning Letters against Bao Jianhua, Jingdezhen Fuxiang Investment Co., Ltd., Bao Danhong, and Ke Xili" ([2021] No. 5). The main content includes: The company's actual controller Bao Jianhua and its concerted actors Jingdezhen Fuxiang Investment Co., Ltd., Bao Danhong, and Ke Xili from March 25, 2019 to January 21, 2021 During the period, when the cumulative change in the total shareholding ratio reached 5%, the company failed to promptly perform reporting and announcement obligations and cease trading in Fuxiang Pharmaceutical shares in accordance with the "Measures for the Administration of Acquisitions of Listed Companies", violating the "Shenzhen Stock Exchange GEM Stock Listing Rules", the "Shenzhen Stock Exchange GEM Stock Listing Guidelines" and other relevant regulations.
Rectification situation: The company is preparing to set up a study group, instructing the Securities Investment Department to produce courseware, and organizing regular and irregular study activities for the company's major shareholders and all directors, supervisors and senior management, so that relevant personnel can fully understand the rules; at the same time, the information disclosure obligors strengthen self-study, strive to improve their understanding and learning of relevant rules, strictly abide by the rules in future market transactions, and prevent the recurrence of the above problems.
(2) China Securities Regulatory Commission Jiangxi Supervision Bureau’s “Decision on Taking Measures to Issue Warning Letters to Jiangxi Fuxiang Pharmaceutical Co., Ltd., Bao Jianhua, Qiao Xiaoguang, and Huang Xiaodong” ([2022] No. 10), Shenzhen Stock Exchange’s “Decision on Notifying and Criticizing Jiangxi Fuxiang Pharmaceutical Co., Ltd. and Related Parties”
On May 12, 2022, the company received the Shenzhen Stock Exchange’s “Decision on Notifying and Criticizing Jiangxi Fuxiang Pharmaceutical Co., Ltd. and Related Parties”, and on July 19, 2022, it received the Jiangxi Supervision Bureau’s “Decision on Taking Measures to Issue Warning Letters against Jiangxi Fuxiang Pharmaceutical Co., Ltd., Bao Jianhua, Qiao Xiaoguang, and Huang Xiaodong” ([2022] 10 No.), the main content includes: the company failed to accurately and completely disclose the orders in hand for the production of mopiravir and remdesivir intermediates, the proportion of revenue, R&D investment, supply status and other matters, resulting in inaccurate and incomplete disclosure of relevant information; the company failed to clarify the rumors in a timely manner after carrying out communication activities with investors, and the company's above-mentioned behavior did not comply with the relevant provisions of the "Information Disclosure Management Measures for Listed Companies".
Rectification situation: ① The company has deeply reflected on the deficiencies in its work and established and improved its internal system. In future work, the company will strictly abide by the relevant provisions of the "Information Disclosure Management System" and "Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies", conduct strict review of the information disclosure content, further verify the authenticity, accuracy and completeness of the content, as well as the degree of impact on the company's financial status, and fully warn of risks. ② The company strengthens the compliance awareness of the company’s directors, supervisors and senior executives, and holds special training meetings on-site and via video. Through training, the company’s directors, supervisors and senior executives and relevant personnel further improve their understanding of laws and regulations such as information disclosure principles. The company and relevant personnel will carefully learn lessons and ensure that the information disclosed is true, accurate and complete. The company will also continue to arrange for directors, supervisors, senior managers and relevant personnel to actively participate in relevant training and learning organized by regulatory authorities such as the China Securities Regulatory Commission, exchanges, and the Association of Listed Companies, in order to further improve the professional judgment and professional quality of directors, supervisors and senior managers, and promote the diligence and responsibility of relevant personnel. ③The company implements the accountability mechanism. The company will further emphasize the responsibilities and obligations that controlling shareholders, actual controllers, all directors, supervisors, senior managers and heads of relevant functional departments should bear in the decision-making, implementation and information disclosure of various major matters. ④ The company will strengthen the monitoring of online public opinion, promptly discover untrue content related to the company, and deal with it in a legal and compliant manner; when the company encounters an unexpected crisis, it will provide the company with corresponding response strategies and suggestions, assist the company in handling the crisis, and formulate a summary afterwards. In the subsequent investor relations management activities, the company will strictly abide by the relevant provisions of the "Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies".
Except for the above, the company has not been subject to regulatory measures by securities regulatory authorities and exchanges in the past five years. The company will strictly regulate its operations in accordance with the relevant regulations and requirements of the securities regulatory authorities and stock exchanges in the "Company Law" and "Securities Law". Under the supervision and guidance of the securities regulatory authorities and exchanges, the company will continue to improve the corporate governance structure, establish and improve internal management and control systems, improve corporate governance levels, and promote the company's sustainable and standardized development. Announcement is hereby made.
Board of Directors of Jiangxi Fuxiang Pharmaceutical Co., Ltd.
July 31, 2026